The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030

被引:9
作者
van Dijk, Marleen [1 ]
Brakenhoff, Sylvia M. [2 ]
Isfordink, Cas J. [3 ,4 ]
Cheng, Wei-Han [5 ]
Blokzijl, Hans [6 ]
Boland, Greet [7 ]
Dofferhoff, Anthonius S. M. [8 ]
van Hoek, Bart [9 ]
van Nieuwkoop, Cees [10 ]
Sonneveld, Milan J. [2 ]
van der Valk, Marc [4 ]
Drenth, Joost P. H. [1 ]
de Knegt, Robert J. [2 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol & Hepatol, NL-6525 GA Nijmegen, Netherlands
[2] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[3] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, NL-3584 CX Utrecht, Netherlands
[4] Univ Amsterdam, Amsterdam UMC, Amsterdam Infect & Immun Inst, Dept Internal Med,Div Infect Dis, NL-1105 AZ Amsterdam, Netherlands
[5] AbbVie Inc, Hlth Econ & Outcomes Res, N Chicago, IL 60064 USA
[6] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, NL-9713 GZ Groningen, Netherlands
[7] Univ Med Ctr Utrecht, Dept Med Microbiol, NL-3584 CX Utrecht, Netherlands
[8] Radboud Univ Nijmegen, Med Ctr, Canisius Wilhelmina Hosp, Dept Internal Med, NL-6532 SZ Nijmegen, Netherlands
[9] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, NL-2333 ZA Leiden, Netherlands
[10] Haga Teaching Hosp, Dept Internal Med, NL-2545 AA The Hague, Netherlands
关键词
hepatitis C; HCV; elimination; model; COVID-19; DIRECT-ACTING ANTIVIRALS; FUTURE DISEASE BURDEN; ACCESS; HIV;
D O I
10.3390/jcm10194562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The Netherlands strives for hepatitis C virus (HCV) elimination, in accordance with the World Health Organization targets. An accurate estimate when HCV elimination will be reached is elusive. We have embarked on a nationwide HCV elimination project (CELINE) that allowed us to harvest detailed data on the Dutch HCV epidemic. This study aims to provide a well-supported timeline towards HCV elimination in The Netherlands. Methods: A previously published Markov model was used, adopting published data and unpublished CELINE project data. Two main scenarios were devised. In the Status Quo scenario, 2020 diagnosis and treatment levels remained constant in subsequent years. In the Gradual Decline scenario, an annual decrease of 10% in both diagnoses and treatments was implemented, starting in 2020. WHO incidence target was disregarded, due to low HCV incidence in The Netherlands (<= 5 per 100,000). Results: Following the Status Quo and Gradual Decline scenarios, The Netherlands would meet WHO's elimination targets by 2027 and 2032, respectively. From 2015 to 2030, liver-related mortality would be reduced by 97% in the Status Quo and 93% in the Gradual Decline scenario. Compared to the Status Quo scenario, the Gradual Decline scenario would result in 12 excess cases of decompensated cirrhosis, 18 excess cases of hepatocellular carcinoma, and 20 excess cases of liver-related death from 2020-2030. Conclusions: The Netherlands is on track to reach HCV elimination by 2030. However, it is vital that HCV elimination remains high on the agenda to ensure adequate numbers of patients are being diagnosed and treated.
引用
收藏
页数:12
相关论文
共 30 条
  • [1] [Anonymous], 2019, WORLD POPULATION PRO
  • [2] [Anonymous], 2016, SEXUALLY TRANSMITTED
  • [3] [Anonymous], 2017, SEXUALLY TRANSMITTED
  • [4] Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
    Binka, Mawuena
    Janjua, Naveed Z.
    Grebely, Jason
    Estes, Chris
    Schanzer, Dena
    Kwon, Jisoo A.
    Shoukry, Naglaa H.
    Kwong, Jeffrey C.
    Razavi, Homie
    Feld, Jordan J.
    Krajden, Mel
    [J]. JAMA NETWORK OPEN, 2020, 3 (05)
  • [5] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
    Blach, Sarah
    Zeuzem, Stefan
    Manns, Michael
    Altraif, Ibrahim
    Duberg, Ann-Sofi
    Muljono, David H.
    Waked, Imam
    Alavian, Seyed M.
    Lee, Mei-Hsuan
    Negro, Francesco
    Abaalkhail, Faisal
    Abdou, Ahmed
    Abdulla, Maheeba
    Abou Rached, Antoine
    Aho, Inka
    Akarca, Ulus
    Al Ghazzawi, Imad
    Al Kaabi, Saad
    Al Lawati, Faryal
    Al Namaani, Khalid
    Al Serkal, Youssif
    Al-Busafi, Said A.
    Al-Dabal, Layla
    Aleman, Soo
    Alghamdi, Abdullah S.
    Aljumah, Abdulrahman A.
    Al-Romaihi, Hamad E.
    Andersson, Monique I.
    Arendt, Vic
    Arkkila, Perttu
    Assiri, Abdullah M.
    Baatarkhuu, Oidov
    Bane, Abate
    Ben-Ari, Ziv
    Bergin, Colm
    Bessone, Fernando
    Bihl, Florian
    Bizri, Abdul R.
    Blachier, Martin
    Blasco, Antonio J.
    Mello, Carlos E. Brandao
    Bruggmann, Philip
    Brunton, Cheryl R.
    Calinas, Filipe
    Chan, Henry L. Y.
    Chaudhry, Asad
    Cheinquer, Hugo
    Chen, Chien-Jen
    Chien, Rong-Nan
    Choi, Moon Seok
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03): : 161 - 176
  • [6] High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands
    Boerekamps, Anne
    Newsum, Astrid M.
    Smit, Colette
    Arends, Joop E.
    Richter, Clemens
    Reiss, Peter
    Rijnders, Bart J. A.
    Brinkman, Kees
    van der Valk, Marc
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (09) : 1352 - 1359
  • [7] Immediate impact of COVID-19 on transplant activity in the Netherlands
    de Vries, A. P. J.
    Alwayn, I. P. J.
    Hoek, R. A. S.
    van den Berg, A. P.
    Ultee, F. C. W.
    Vogelaar, S. M.
    Haase-Kromwijk, B. J. J. M.
    Heemskerk, M. B. A.
    Hemke, A. C.
    Nijboer, W. N.
    Schaefer, B. S.
    Kuiper, M. A.
    de Jonge, J.
    van der Kaaij, N. P.
    Reinders, M. E. J.
    [J]. TRANSPLANT IMMUNOLOGY, 2020, 61
  • [8] Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands Comment
    Dinmohamed, Avinash G.
    Visser, Otto
    Verhoeven, Rob H. A.
    Louwman, Marieke W. J.
    van Nederveen, Francien H.
    Willems, Stefan M.
    Merkx, Matthias A. W.
    Lemmens, Valery E. P. P.
    Nagtegaal, Iris D.
    Siesling, Sabine
    [J]. LANCET ONCOLOGY, 2020, 21 (06) : 750 - 751
  • [9] Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries
    Falla, A. M.
    Ahmad, A. A.
    Duffell, E.
    Noori, T.
    Veldhuijzen, I. K.
    [J]. BMC INFECTIOUS DISEASES, 2018, 18
  • [10] Progress towards hepatitis C virus elimination in high-income countries: An updated analysis
    Gamkrelidze, Ivane
    Pawlotsky, Jean-Michel
    Lazarus, Jeffrey V.
    Feld, Jordan J.
    Zeuzem, Stefan
    Bao, Yanjun
    Gabriela Pires dos Santos, Ana
    Sanchez Gonzalez, Yuri
    Razavi, Homie
    [J]. LIVER INTERNATIONAL, 2021, 41 (03) : 456 - 463